Additionally, our research on the l11Jus8 mutant may inform future investigations into chemotherapy-induced cardiotoxicity associated with inhibition of ERBB2 signalling, as new anti-cancer therapeutics are being designed to target the ERBB2 kinase domain [67]. Here, ERBB2 is linked to cancer.